Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab in adults with type 2 diabetes mellitus and hypercholesterolemia or mixed dyslipidemia
2015-004711-21Phase 3Completed
- Sponsor
- Amgen
- Start
- May 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia and combined dyslipidaemia comparing Evolocumab monthly with Placebo monthly (2 arms). Primary endpoint: Mean percent change from baseline in LDL-C at weeks 10 and 12. Started May 2016; status: completed.
02
Drugs
evolocumab
03
Conditions
hypercholesterolemiacombined dyslipidaemia
Beyond the preview
Go deeper on 2015-004711-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004711-21.